COLCHICINE FOR PREVENTION OF PERIOPERATIVE ATRIAL FIBRILLATION IN PATIENTS UNDERGOING THORACIC SURGERY: PILOT STUDY

Bessissow, Amal

Please use this identifier to cite or link to this item: http://hdl.handle.net/11375/20112

Full metadata record

DC Field	Value	Language
dc.contributor.advisor	Devereaux, P.J.	-
dc.contributor.advisor	Bhandari, Mohit	-
dc.contributor.advisor	Lamy, Andre	-
dc.contributor.author	Bessissow, Amal	-
dc.date.accessioned	2016-08-11T14:58:51Z	-
dc.date.available	2016-08-11T14:58:51Z	-
dc.date.issued	2016	-
dc.identifier.uri	http://hdl.handle.net/11375/20112	-
dc.description.abstract	BACKGROUND: Up to 20% of patients will develop postoperative atrial fibrillation (POAF) or atrial flutter after thoracic surgery. These arrhythmias have been associated with serious complications such as death, stroke, and increased hospital length of stay. OBJECTIVES: This study aimed to determine: the feasibility of recruiting patients undergoing thoracic surgery to a randomized controlled trial (RCT) comparing colchicine and placebo for the prevention of POAF, the resources required to conduct a large trial, and compliance with the study drug. The main efficacy outcome was POAF or atrial flutter within 30 days of randomization. METHODS: Patients aged 55 years and older undergoing a resection of tumor in the lung were recruited from two Canadian centers. Participants were randomly assigned to receive colchicine 0.6mg or placebo orally within 4 hours before surgery. Postoperatively, patients received colchicine 0.6mg or placebo twice daily for 10 days. Troponin measurement and an electrocardiogram were performed daily during the first 3 days after surgery. Patients’ follow-up occurred in hospital and at 30-days. RESULTS: One hundred patients were randomized (49 to colchicine and 51 to placebo) over a period of 12 months. All patients completed the 30-day follow-up. The mean staff time required to recruit and follow-up each patient was 165 minutes. 71% of patients completed the study drug course without interruption. New POAF or atrial flutter occurred in 5 (10.2%) of the patients in the colchicine group and 7 (13.7%) of the patients in the placebo group (adjusted hazard ratio 0.69; 95% confidence interval, 0.20-2.34; p= 0.55). CONCLUSION: These results show the feasibility of COP-AF pilot study. This pilot study will serve as the foundation for the large multicentre COP-AF RCT.	en_US
dc.language.iso	en	en_US
dc.title	COLCHICINE FOR PREVENTION OF PERIOPERATIVE ATRIAL FIBRILLATION IN PATIENTS UNDERGOING THORACIC SURGERY: PILOT STUDY	en_US
dc.type	Thesis	en_US
dc.contributor.department	Health Research Methodology	en_US
dc.description.degreetype	Thesis	en_US
dc.description.degree	Master of Science (MSc)	en_US
dc.description.layabstract	In patients undergoing thoracic surgery, as many as 1 in 5 patients will develop atrial fibrillation (fast disorganized chaotic heart beats). This may lead to complications including death, stroke (clot in the brain), and longer hospital stay. One theory is that atrial fibrillation is due to excessive inflammation in the body after surgery. The purpose of this pilot study is to determine whether it is feasible to conduct a large study to test the effect of colchicine, an anti-inflammatory drug, on the risk of developing atrial fibrillation after thoracic surgery. Participants were randomly assigned to take either colchicine or placebo starting on the day of the surgery for 10 consecutive days. We documented the presence or absence of atrial fibrillation after surgery. We demonstrated feasibility of enrolment, application of the intervention, and follow up of 100 participants. The results of this study will be useful in developing a larger multicentre trial.	en_US
Appears in Collections:	Open Access Dissertations and Theses

Files in This Item:

File	Description	Size	Format
Bessissow_Amal_finalsubmission2016July_MSc.pdf Open Access	Master's thesis manuscript	992.59 kB	Adobe PDF	View/Open

Show simple item record